

Prior Authorization (PA) Documentation Checklist for XDEMVY[™]

Tarsus C⊗nnect[™]

Some payers will require a PA for XDEMVY. Specific requirements may vary. Use this checklist to ensure that sufficient information is documented to help your appropriate patients access XDEMVY. In addition, see helpful PA submission tips on the next page.

Patient Demographic & Insurance Information

- Patient name, gender, and date of birth
- Pharmacy benefit policy number and group number

Eye Care Professional Information

- Prescriber name and provider identification number
- Specialty (eg, ophthalmology, optometry)

Prescribed Treatment

- Medication XDEMVY
- Dosing and duration 1 drop into each eye twice daily (approximately 12 hours apart) for 6 weeks¹
- Initial PA or Reauthoriziation

Clinical Diagnosis

- For your patients with Demodex blepharitis, it is important to indicate the diagnosis and related ICD-10 diagnosis code(s), for example²:
 - H01.00_ (Unspecified blepharitis_)
 - B88.0 (Other acariasis)
- Date of diagnosis

 Clinician-observed signs and symptoms associated with *Demodex* blepharitis (if required by payer)

Indication and Usage

XDEMVY is indicated for the treatment of *Demodex* blepharitis.

Important Safety Information WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Please see additional Important Safety Information on the next page. Please <u>click</u> for full Prescribing Information.



xdemvy[™] Helpful Tips for PA Submission for XDEMVY[™]

Provide key information with your ePrescription to one of the following nationwide pharmacies supplying XDEMVY, so they can start the PA process

AllianceRx Walgreens Pharmacy Phone: 1-800-424-9002 Fax: 1-800-874-9179

> **Carepoint Pharmacy** Phone: 1-855-237-9112 Fax: 1-855-237-9113

BlinkRx Phone: 1-833-919-4942 Fax: 1-866-585-4631

CVS Specialty Pharmacy Phone: 1-800-237-2767 Fax: 1-800-323-2445

If a CoverMyMeds notification is received, follow up promptly by completing any missing information and signing the PA.

Providing complete information and documentation as required by a patient's payer will be critical for avoiding PA denials.

Helpful Downloadable Resources at <u>xdemvy.com</u>

Sample Letter of **Medical Necessity** Sample Letter of Appeal

For more information and helpful resources, visit xdemvy.com or call Tarsus Connect at 1-866-846-3092

Important Safety Information (continued)

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration. **ADVERSE REACTIONS:** The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please click for full Prescribing Information.

References: 1. XDEMVY Prescribing Information. Tarsus Pharmaceuticals, Inc. 2023. 2. Centers for Medicare & Medicaid Services. 2023 ICD-10-CM April 1, 2023. Accessed August 2, 2023. https://www.cms.gov/medicare/icd-10/2023-icd-10-cm

